Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683176 | 0.77 | CA12 (0.42) | TSHRCYP1A2SMN1; SMN2CYP2D6PKM | |
| SCHEMBL5492430 | 0.76 | CYP2C19 (0.35) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL424239 | 0.76 | TAAR1 (0.47) | ALDH1A1TAAR1 | |
| SCHEMBL8489804 | 0.73 | CCR5 (0.41) | TSHRCYP1A2SMN1; SMN2CYP2D6PKM | |
| SCHEMBL11124275 | 0.73 | TSHR (0.38) | TSHRCYP1A2SMN1; SMN2CYP2D6PKM | |
| SCHEMBL11124263 | 0.73 | TSHR (0.38) | TSHRCYP1A2SMN1; SMN2CYP2D6PKM | |
| SCHEMBL3108768 | 0.72 | TAAR1 (0.37) | CYP2D6GRM2GRM3TAAR1HTR2A | |
| SCHEMBL9865734 | 0.72 | KDM4E (0.50) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL9572737 | 0.70 | SMN1; SMN2 (0.39) | TSHRCYP1A2SMN1; SMN2CYP2D6PKM | |
| SCHEMBL7108780 | 0.69 | ANPEP (0.39) | TAAR1HTR2AHRH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108157-A1 | FORMULATIONS OF (S)-3-(1-(9H-PURIN-6-YLAMINO)ETHYL)-8-CHLORO-2-PHENYLISOQUINOLIN-1(2H)-ONE | INTELLIKINE LLC | 2023-04-06 | — | — | US | disclosed |
| US-11312718-B2 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one | INFINITY PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200385388-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | INFINITY PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10550122-B2 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3238722-B1 | SOLID FORMS OF ISOQUINOLINONES | INFINITY PHARMACEUTICALS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20180273535-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | HCR COLLATERAL MANAGEMENT, LLC | 2018-09-27 | — | — | US | disclosed |
| US-9840505-B2 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-RE46621-E1 | Processes for preparing isoquinolinones and solid forms of isoquinolinones | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| EP-3238722-A1 | SOLID FORMS OF ISOQUINOLINONES | Infinity Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2663309-B1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | INFINITY PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9290497-B2 | Processes for preparing isoquinolinones and solid forms of isoquinolinones | INFINITY PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140371450-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | HCR COLLATERAL MANAGEMENT, LLC | 2014-12-18 | — | — | US | disclosed |
| US-8809349-B2 | Processes for preparing isoquinolinones and solid forms of isoquinolinones | INFINITY PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2663309-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | Infinity Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120184568-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | HCR COLLATERAL MANAGEMENT, LLC | 2012-07-19 | — | — | US | disclosed |
| WO-2012097000-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | REN PINGDA (US) | 2012-07-19 | — | — | WO | disclosed |
| US-7759494-B2 | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl)ethoxy-carbonyl]-5-oxazolidine carboxylic acids | DABUR INDIA LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20080064887-A1 | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl)ethoxycarbon1]-5-oxazolidine carboxylic acids | DABUR INDIA LIMITED (IN) | 2008-03-13 | — | — | US | disclosed |
| US-7247738-B2 | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids | DABUR INDIA LIMITED (IN) | 2007-07-24 | — | — | US | disclosed |
| US-20030229135-A1 | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl)ethoxycarbonyl]-5-oxazolidine carboxylic acids | DABUR PHARMA LIMITED (IN) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312718-B2 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one | PIK3CA, AKT3, PIK3CD | ALDH1A1 3879/4885TSHR 3931/4885CYP1A2 1056/4885 |
| US-20030229135-A1 | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl)ethoxycarbonyl]-5-oxazolidine carboxylic acids | TBCA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TUBAL3 | ALDH1A1 1025/4885TSHR 3448/4885CYP1A2 3634/4885 |
| US-20200385388-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | PIK3CA, PDPK1, AKT3 | ALDH1A1 3633/4885TSHR 4045/4885CYP1A2 621/4885 |
| US-20120184568-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | PIK3CA, PDPK1, AKT3 | ALDH1A1 3633/4885TSHR 4045/4885CYP1A2 621/4885 |
| US-10550122-B2 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof | PLK2, PLK3, PIK3CA | ALDH1A1 3271/4885TSHR 3962/4885CYP1A2 1122/4885 |
| US-20230108157-A1 | FORMULATIONS OF (S)-3-(1-(9H-PURIN-6-YLAMINO)ETHYL)-8-CHLORO-2-PHENYLISOQUINOLIN-1(2H)-ONE | PIK3CA, PIK3CD, PIK3CG | ALDH1A1 3059/4885TSHR 4240/4885CYP1A2 670/4885 |
| US-20140371450-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | PIK3CA, PDPK1, AKT3 | ALDH1A1 3633/4885TSHR 4045/4885CYP1A2 621/4885 |
| US-20180273535-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | PLK3, PLK2, PLK4 | ALDH1A1 3591/4885TSHR 3900/4885CYP1A2 773/4885 |
| US-20080064887-A1 | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl)ethoxycarbon1]-5-oxazolidine carboxylic acids | TBCA, TUBAL3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 811/4885TSHR 3334/4885CYP1A2 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.